Patents by Inventor Robert Abramowitz

Robert Abramowitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7135465
    Abstract: Extended dosage forms of stavudine are provided comprising beadlets formed by extrusion-spheronization and coated with a seal coating. The beadlets are also coated with a modified release coating such that a hard gelatin capsule containing such beadlets will provide blood levels of stavudine over approximately 24 hours. The beadlets are prepared from a dry blend of stavudine, a spheronizing agent, a suitable diluent and a stabilizing amount of magnesium stearate. The magnesium stearate, in contrast to other similar pharmaceutical adjuncts, has been found to stabilize stavudine against degradation due to hydrolysis in the presence of the limited amount of water necessary for the extrusion-spheronization process. Also included in the scope of the invention are hard gelatin capsules containing, in addition to the stavudine beadlets, similar beadlets containing other therapeutic agents utilized to treat retroviral infections.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: November 14, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Abramowitz, Denise M. O'Donoghue, Nemichand B. Jain
  • Publication number: 20020002147
    Abstract: Extended dosage forms of stavudine are provided comprising beadlets formed by extrusion-spheronization and coated with a seal coating. The beadlets are also coated with a modified release coating such that a hard gelatin capsule containing such beadlets will provide blood levels of stavudine over approximately 24 hours. The beadlets are prepared from a dry blend of stavudine, a spheronizing agent, a suitable diluent and a stabilizing amount of magnesium stearate. The magnesium stearate, in contrast to other similar pharmaceutical adjuncts, has been found to stabilize stavudine against degradation due to hydrolysis in the presence of the limited amount of water necessary for the extrusion-spheronization process. Also included in the scope of the invention are hard gelatin capsules containing, in addition to the stavudine beadlets, similar beadlets containing other therapeutic agents utilized to treat retroviral infections.
    Type: Application
    Filed: March 29, 2001
    Publication date: January 3, 2002
    Inventors: Robert Abramowitz, Denise M. O'Donoghue, Nemichand B. Jain
  • Patent number: 5536507
    Abstract: A three component pharmaceutical formulation of one or more pharmacologically active substances such that greater than 80% of the pharmacologically active substance will be released in the large intestine. The first component comprises the pharmacologically active substance, microcrystalline cellulose, a pH-sensitive polymer, and optionally an osmotic agent. The second component is a delayed release coating, and the third component is an enteric coating.
    Type: Grant
    Filed: June 24, 1994
    Date of Patent: July 16, 1996
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Abramowitz, Sunanda A. Ranadive, Sailesh A. Varia, Nemichand B. Jain
  • Patent number: 5158777
    Abstract: A formulation comprising captopril within an enteric or delayed release coated pH stable core combined with additional captopril that is available for immediate release following administration.
    Type: Grant
    Filed: August 16, 1991
    Date of Patent: October 27, 1992
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Robert Abramowitz, Yatinda M. Joshi, Nemichand B. Jain